ANKRD17
Basic information
Region (hg38): 4:73073376-73258798
Links
Phenotypes
GenCC
Source:
- Chopra-Amiel-Gordon syndrome (Strong), mode of inheritance: AD
- syndromic intellectual disability (Strong), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Chopra-Amiel-Gordan syndrome | AD | Allergy/Immunology/Infectious | Among other findings, the condition may involve susceptibility to infections, and awareness may allow preventative measures and early and aggressive treatment of infections | Allergy/Immunology/Infectious; Craniofacial; Musculoskeletal; Neurologic; Ophthalmologic | 33909992 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (3 variants)
- Chopra-Amiel-Gordon syndrome (3 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ANKRD17 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 12 | |||||
missense | 11 | 137 | 14 | 163 | ||
nonsense | 3 | |||||
start loss | 0 | |||||
frameshift | 12 | |||||
inframe indel | 6 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | 2 | |||
non coding | 3 | |||||
Total | 6 | 19 | 146 | 22 | 6 |
Variants in ANKRD17
This is a list of pathogenic ClinVar variants found in the ANKRD17 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
4-73076240-C-G | Inborn genetic diseases | Uncertain significance (Oct 26, 2022) | ||
4-73076244-T-C | Chopra-Amiel-Gordon syndrome | Uncertain significance (Apr 06, 2023) | ||
4-73076265-T-C | Inborn genetic diseases | Uncertain significance (Nov 07, 2022) | ||
4-73076278-G-C | ANKRD17-related disorder | Likely benign (Feb 28, 2022) | ||
4-73076278-G-T | Inborn genetic diseases | Uncertain significance (Sep 27, 2021) | ||
4-73076945-G-C | Uncertain significance (Feb 29, 2024) | |||
4-73076948-G-T | Inborn genetic diseases | Uncertain significance (Dec 14, 2023) | ||
4-73076961-C-T | Lip and oral cavity carcinoma | association (-) | ||
4-73076963-T-G | Chopra-Amiel-Gordon syndrome • Inborn genetic diseases | Uncertain significance (Aug 10, 2023) | ||
4-73076977-A-G | Inborn genetic diseases | Uncertain significance (May 14, 2024) | ||
4-73077028-A-G | Uncertain significance (Sep 20, 2022) | |||
4-73077438-G-A | Chopra-Amiel-Gordon syndrome | Pathogenic (Jul 16, 2023) | ||
4-73077472-G-T | Inborn genetic diseases | Uncertain significance (Apr 26, 2023) | ||
4-73077487-GTGGATCA-G | Chopra-Amiel-Gordon syndrome | Likely pathogenic (-) | ||
4-73077488-T-G | Chopra-Amiel-Gordon syndrome | Uncertain significance (Sep 16, 2021) | ||
4-73077533-T-C | ANKRD17-related disorder | Uncertain significance (May 17, 2023) | ||
4-73078627-G-A | not specified | Likely benign (Oct 12, 2023) | ||
4-73078647-T-C | Inborn genetic diseases | Uncertain significance (Dec 20, 2023) | ||
4-73078657-T-A | Inborn genetic diseases | Uncertain significance (Aug 28, 2023) | ||
4-73078696-T-C | Inborn genetic diseases | Uncertain significance (Sep 27, 2022) | ||
4-73078712-A-T | ANKRD17-related disorder | Uncertain significance (Jan 26, 2023) | ||
4-73078739-T-G | Uncertain significance (Nov 21, 2022) | |||
4-73078750-G-C | Chopra-Amiel-Gordon syndrome | Likely pathogenic (Mar 01, 2022) | ||
4-73078803-T-C | Inborn genetic diseases | Uncertain significance (Dec 15, 2023) | ||
4-73078831-C-T | Inborn genetic diseases | Likely benign (Oct 25, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ANKRD17 | protein_coding | protein_coding | ENST00000358602 | 34 | 185423 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 1.88e-15 | 125741 | 0 | 7 | 125748 | 0.0000278 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 5.36 | 802 | 1.36e+3 | 0.591 | 0.0000678 | 16805 |
Missense in Polyphen | 97 | 300.9 | 0.32237 | 3523 | ||
Synonymous | 0.181 | 490 | 495 | 0.990 | 0.0000260 | 5421 |
Loss of Function | 9.13 | 2 | 101 | 0.0198 | 0.00000516 | 1312 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000180 | 0.000163 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000272 | 0.0000264 |
Middle Eastern | 0.000180 | 0.000163 |
South Asian | 0.00 | 0.00 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Could play pivotal roles in cell cycle and DNA regulation (PubMed:19150984). Involved in innate immune defense against viruse by positively regulating the viral dsRNA receptors DDX58 and IFIH1 signaling pathways (PubMed:22328336). Involves in NOD2- and NOD1-mediated responses to bacteria suggesting a role in innate antibacterial immune pathways too (PubMed:23711367). Target of enterovirus 71 which is the major etiological agent of HFMD (hand, foot and mouth disease) (PubMed:17276651). Could play a central role for the formation and/or maintenance of the blood vessels of the circulation system (By similarity). {ECO:0000250|UniProtKB:Q99NH0, ECO:0000269|PubMed:17276651, ECO:0000269|PubMed:19150984, ECO:0000269|PubMed:22328336, ECO:0000269|PubMed:23711367}.;
Intolerance Scores
- loftool
- 0.0262
- rvis_EVS
- -2.94
- rvis_percentile_EVS
- 0.55
Haploinsufficiency Scores
- pHI
- 0.303
- hipred
- Y
- hipred_score
- 0.708
- ghis
- 0.663
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.819
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ankrd17
- Phenotype
- embryo phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); homeostasis/metabolism phenotype; growth/size/body region phenotype; muscle phenotype;
Gene ontology
- Biological process
- blood vessel maturation;regulation of DNA replication;viral process;defense response to bacterium;positive regulation of I-kappaB kinase/NF-kappaB signaling;innate immune response;positive regulation of cell cycle;negative regulation of smooth muscle cell differentiation;positive regulation of G1/S transition of mitotic cell cycle;positive regulation of MDA-5 signaling pathway;positive regulation of RIG-I signaling pathway
- Cellular component
- chromatin;nucleus;cytoplasm;membrane;nuclear membrane
- Molecular function
- chromatin binding;RNA binding;protein binding